Payment overview · 2025
General Payments
$909.30
42 reported records · 14 companies
Healthcare provider profile · identity verified
Ketki P Mougey, MD
Allopathic & Osteopathic Physicians|Family Medicine · HILLARD, OH · NPI 1871671024
Verified facts
What the public records show
CMS Open Payments records show Ketki P Mougey, MD received $909.30 in general payments during 2025 across 42 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $341.41 | 37.5% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $208.35 | 22.9% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $142.64 | 15.7% | 9 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $31.12 | 3.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.27 | 3.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.22 | 2.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.71 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.00 | 2.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.62 | 1.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.13 | 1.9% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.12 | 1.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.70 | 1.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.63 | 1.7% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $15.38 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $909.30 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $169.94 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $123.70 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $97.97 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $83.53 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $83.53 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $82.34 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $68.24 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $47.77 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.13 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $31.12 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $30.27 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $26.85 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 94 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
94 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 495 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 230 | 64 |
| Omeprazole | Omeprazole | 226 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 223 | 59 |
| Lisinopril | Lisinopril | 216 | 57 |
| Losartan Potassium | Losartan Potassium | 204 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 44 |
| Gabapentin | Gabapentin | 160 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 152 | 40 |
| Alprazolam | Alprazolam | 130 | 25 |
| Potassium Chloride | Potassium Chloride | 122 | 35 |
| Tramadol Hcl | Tramadol Hcl | 110 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 24 |
| Simvastatin | Simvastatin | 103 | 32 |
| Sertraline Hcl | Sertraline Hcl | 101 | 24 |
| Montelukast Sodium | Montelukast Sodium | 95 | 24 |
| Farxiga | Dapagliflozin Propanediol | 94 | 18 |
| Metformin Hcl | Metformin Hcl | 94 | 33 |
| Metformin Hcl Er | Metformin Hcl | 94 | 27 |
| Bupropion Xl | Bupropion Hcl | 91 | 18 |
| Furosemide | Furosemide | 86 | 25 |
| Alendronate Sodium | Alendronate Sodium | 80 | 20 |
| Carvedilol | Carvedilol | 77 | 20 |
| Prednisone | Prednisone | 74 | 52 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 21 |
| Jardiance | Empagliflozin | 71 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 65 | suppressed |
| Eliquis | Apixaban | 63 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | suppressed |
| Amoxicillin | Amoxicillin | 55 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 15 |
| Trazodone Hcl | Trazodone Hcl | 54 | 17 |
| Buspirone Hcl | Buspirone Hcl | 53 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 14 |
| Synthroid | Levothyroxine Sodium | 50 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 12 |
| Enalapril Maleate | Enalapril Maleate | 48 | 13 |
| Valsartan | Valsartan | 48 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 20 |
| Lorazepam | Lorazepam | 47 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | 12 |
| Azithromycin | Azithromycin | 43 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Temazepam | Temazepam | 43 | suppressed |
| Diazepam | Diazepam | 42 | suppressed |
| Meloxicam | Meloxicam | 42 | 14 |
| Clonidine Hcl | Clonidine Hcl | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 13 |
| Celecoxib | Celecoxib | 38 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Glipizide | Glipizide | 35 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 35 | 15 |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 12 |
| Acarbose | Acarbose | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 20 |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 20 |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Klor-Con M10 | Potassium Chloride | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Movantik | Naloxegol Oxalate | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 12 | suppressed |
| Nucynta Er | Tapentadol Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $909.30 · 42 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, CREON, ENFLONSIA, EVENITY, FARXIGA, Flector, GARDASIL 9, INCEPTIV, Licart, Ozempic, PROQUAD, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, Tirosint, UBRELVY, VAXNEUVANCE, VRAYLAR, Veozah, Wegovy, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error